McKesson Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian S. Tyler
- Full Time Employees
- 42,300
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 6555 State Highway 161 Irving TX United States of America 75039
- IPO Date
- Nov 10, 1994
- CIK
- 0000927653
- Website
- mckesson.com
- Similar Companies
- Business
- McKesson Corporation (NYSE: MCK) operates as a diversified healthcare services company, primarily engaged in pharmaceutical distribution, medical-surgical supply distribution, oncology and multispecialty solutions, and prescription technology services. The company distributes pharmaceuticals and medical supplies through its North American Pharmaceutical segment, which serves retail and community pharmacies, specialty care settings, and health systems across the United States and Canada via a network of distribution centers; its Oncology and Multispecialty segment provides practice management, technology solutions, specialty drug distribution, clinical trial services, group purchasing, and pharmacy solutions for community-based oncology practices and providers in retina and ophthalmology; its Medical-Surgical Solutions segment merchandises and distributes more than 285,000 national brand products alongside McKesson's own brands of medical-surgical supplies, pharmaceuticals, laboratory equipment, and supplies to physician offices, surgery centers, long-term care providers, home health agencies, health systems, government facilities, and online retailers in the United States; and its Prescription Technology Solutions segment offers medication access, affordability, and adherence programs, including prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support connecting patients, pharmacies, providers, payers, and biopharma companies. [fetch:https://www.mckesson.com/about-us/business-segments/] Founded in 1833 and headquartered in Irving, Texas, McKesson serves healthcare providers, pharmacies, biopharma manufacturers, governments, and consumers primarily in North America, with additional distribution and retail operations in Norway, which it agreed to sell in August 2025. [fetch:https://www.mckesson.com/about-us/history/] In recent strategic developments, McKesson acquired a controlling interest in Community Oncology Revitalization Enterprise Ventures (Core Ventures), associated with Florida Cancer Specialists & Research Institute, for $2.49 billion in August 2024 to bolster oncology care; welcomed Florida Cancer Specialists as a member of The US Oncology Network; acquired a controlling interest in PRISM Vision Group to expand into ophthalmology and retina care; formed a joint venture between US Oncology Research and HCA Healthcare's Sarah Cannon Research Institute to advance oncology research and clinical trials; and announced in September 2025 a corporate restructuring into four segments—North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—effective fiscal 2026, alongside plans to separate the Medical-Surgical Solutions segment and updated long-term growth targets including 13% to 16% adjusted earnings per share growth. [fetch:https://www.mckesson.com/about-us/history/]
Company News
Baird Financial Group Inc. Has $29.98 Million Holdings in McKesson Corporation $MCK
McKesson Corporation $MCK Shares Sold by Allworth Financial LP
McKesson (MCK) Suffers a Larger Drop Than the General Market: Key Insights
PRIVACY ALERT: AWKO Law LLP Investigating McKesson for Data Breach Affecting 284 Million Patient Records
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates
Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural Upside
McKesson Corporation $MCK Shares Acquired by Barlow Wealth Partners LLC
Here's Why McKesson (MCK) is a Strong Momentum Stock
Here's Why McKesson (MCK) is a Strong Growth Stock
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
Beacon Pointe Advisors LLC Purchases New Stake in McKesson Corporation $MCK
McKesson to Acquire Precision Medicine Group to Strengthen Services
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
McKesson to buy Precision Medicine Group in about $2.25 billion deal
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?